Company Filing History:
Years Active: 2022
Title: Debashree Banerjee: Innovating Cancer Treatment through Anti-PODXL Antibodies
Introduction: Debashree Banerjee, an accomplished inventor based in Fremont, CA, has made significant contributions to the field of cancer treatment. With her groundbreaking patent focused on the Anti-PODXL antibody MAI1738, she aims to provide a therapeutic solution for various types of cancers that overexpress the podocalyxin-like protein precursor isoform 2 (PODXL-v2).
Latest Patents: Debashree holds a patent for the Anti-PODXL antibody MAI1738 and its utilization in cancer therapy. This innovative therapeutic agent addresses the treatment, prevention, and diagnosis of multiple cancers, including gastric cancers, prostate cancer, and others. The invention emphasizes the significance of targeting cells overexpressing PODXL-v2 and its variants, which are linked to numerous aggressive cancer types.
Career Highlights: Debashree is currently employed at Medabome, Inc., where she actively contributes to the research and development of advanced cancer therapies. Her patent illustrates her expertise in monoclonal antibodies, specifically the MAb1738, which has demonstrated the capacity to inhibit cancer cell proliferation and impede the growth and spread of cancer in preclinical models.
Collaborations: Throughout her career, Debashree has worked alongside distinguished colleagues such as Mason Lu and Qinhong Ma. Their collaboration underscores the importance of teamwork in advancing cancer research and therapeutics, fostering an environment that encourages innovation and discovery.
Conclusion: Debashree Banerjee's contributions to cancer treatment through her patent on the Anti-PODXL antibody MAI1738 reflect her dedication to improving patient outcomes. As cancer research evolves, her work at Medabome, Inc. and collaboration with esteemed coworkers will undoubtedly play a pivotal role in shaping the future of effective cancer therapies.